<DOC>
	<DOC>NCT00507793</DOC>
	<brief_summary>To evaluate the safety and efficacy of different doses of cyclosporine given concomitantly with a fixed dose of sirolimus in kidney transplant recipients.</brief_summary>
	<brief_title>Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus</brief_title>
	<detailed_description>To evaluate the safety and efficacy of different doses of cyclosporine given concomitantly with a fixed dose of sirolimus in kidney transplant recipients. Cyclosporine blood levels, graft rejection rates and renal function will be assessed.</detailed_description>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion criteria At least 18 years of age Endstage renal disease in patients receiving a primary or secondary renal allograft from a cadaveric, livingunrelated, or livingrelated mismatched donor Patients with secondary kidney transplant must have maintained primary graft for at least 6 months Exclusion criteria Antibody induction within one week of current transplantation Multiorgan transplants Patients at highrisk of rejection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>